JP2019514945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514945A5 JP2019514945A5 JP2018557398A JP2018557398A JP2019514945A5 JP 2019514945 A5 JP2019514945 A5 JP 2019514945A5 JP 2018557398 A JP2018557398 A JP 2018557398A JP 2018557398 A JP2018557398 A JP 2018557398A JP 2019514945 A5 JP2019514945 A5 JP 2019514945A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- general formula
- acute
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 8
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 8
- 230000001154 acute effect Effects 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000030090 Acute Disease Diseases 0.000 claims 4
- 206010007556 Cardiac failure acute Diseases 0.000 claims 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 4
- 208000003782 Raynaud disease Diseases 0.000 claims 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000010060 microvascular dysfunction Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011461 pre-eclampsia Diseases 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- -1 trifluoromethoxy, ethoxycarbonyl Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 150000001879 copper Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 claims 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- PXTOBNKJKFQOKG-ZDUSSCGKSA-N 5-[[3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-1,2,4-triazol-1-yl]methyl]-2-[3-(trifluoromethoxy)pyridin-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound ClC1=CC=C(C=C1)C1=NN(C(N1C[C@@H](C(F)(F)F)O)=O)CC1=NN(C(=N1)C(=O)N)C1=NC=CC=C1OC(F)(F)F PXTOBNKJKFQOKG-ZDUSSCGKSA-N 0.000 description 1
- AKFANCNULCXNMQ-ZDUSSCGKSA-N 5-[[3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-1,2,4-triazol-1-yl]methyl]-2-[3-(trifluoromethyl)pyridin-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound ClC1=CC=C(C=C1)C1=NN(C(N1C[C@@H](C(F)(F)F)O)=O)CC1=NN(C(=N1)C(=O)N)C1=NC=CC=C1C(F)(F)F AKFANCNULCXNMQ-ZDUSSCGKSA-N 0.000 description 1
- IBWNUWSYEJOUAH-UHFFFAOYSA-N CCC(C(F)(F)F)O Chemical compound CCC(C(F)(F)F)O IBWNUWSYEJOUAH-UHFFFAOYSA-N 0.000 description 1
- 0 O=C(C1(C2OC12)Cl)O*I Chemical compound O=C(C1(C2OC12)Cl)O*I 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16168165 | 2016-05-03 | ||
| EP16168165.5 | 2016-05-03 | ||
| PCT/EP2017/060356 WO2017191102A1 (en) | 2016-05-03 | 2017-05-02 | Amide-substituted pyridinyltriazole derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514945A JP2019514945A (ja) | 2019-06-06 |
| JP2019514945A5 true JP2019514945A5 (enExample) | 2020-06-11 |
| JP6932140B2 JP6932140B2 (ja) | 2021-09-08 |
Family
ID=55910850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557398A Expired - Fee Related JP6932140B2 (ja) | 2016-05-03 | 2017-05-02 | アミド置換ピリジニルトリアゾール誘導体およびその用途 |
Country Status (42)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| AU2017259872B2 (en) * | 2016-05-03 | 2021-06-24 | Bayer Pharma Aktiengesellschaft | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives |
| EP3452457B1 (en) * | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
| JP7033079B2 (ja) | 2016-05-03 | 2022-03-09 | バイエル・ファルマ・アクティエンゲゼルシャフト | 芳香族スルホンアミド誘導体 |
| US10893352B2 (en) * | 2016-08-24 | 2021-01-12 | Matthew Hawkes | Programmable interactive stereo headphones with tap functionality and network connectivity |
| WO2018163204A1 (en) * | 2017-03-08 | 2018-09-13 | Yogee's Bioinnovations Private Limited | Cathepsin-d and angiogenesis inhibitors and compositions thereof for treating breast cancer |
| CA3072427C (en) | 2017-08-08 | 2023-12-05 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| WO2019081307A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| US11230540B2 (en) | 2017-10-24 | 2022-01-25 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US20210253557A1 (en) | 2017-10-24 | 2021-08-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| EA202091025A1 (ru) | 2017-10-24 | 2020-07-30 | Байер Акциенгезельшафт | Пролекарства замещенных триазольных производных и их применения |
| EP3700898A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| CA3079770A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| US11020351B2 (en) * | 2018-03-26 | 2021-06-01 | Hetero Labs Limited | Stable bilayer tablet compositions |
| US20210016350A1 (en) * | 2018-04-10 | 2021-01-21 | Hewlett-Packard Development Company, L.P. | Preheat dyed build materials with preheating sources |
| JP7279200B2 (ja) * | 2019-12-24 | 2023-05-22 | 東京エレクトロン株式会社 | 成膜方法及び成膜システム |
| WO2021259852A1 (en) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives |
| WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
| EP4626419A1 (en) * | 2022-11-29 | 2025-10-08 | The United States Government as represented by the Department of Veterans Affairs | Eif4a1 inhibitors with antitumor activity |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3042466A1 (de) | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| US5468448A (en) | 1989-12-28 | 1995-11-21 | Ciba-Geigy Corporation | Peroxide disinfection method and devices therefor |
| DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| CA2109524A1 (en) | 1991-05-10 | 1992-11-11 | Prasun K. Chakravarty | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
| WO1993017681A1 (en) | 1992-03-02 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| SK94393A3 (en) | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| US6844005B2 (en) | 2002-02-25 | 2005-01-18 | Trutek Corp | Electrostatically charged nasal application product with increased strength |
| FR2708608B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
| US5897858A (en) | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| US20010020100A1 (en) | 1994-06-14 | 2001-09-06 | G.D. Searle & Co. | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders |
| JP3589633B2 (ja) | 1997-12-17 | 2004-11-17 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| DE19816882A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Triazolone mit neuroprotektiver Wirkung |
| CA2338304A1 (en) | 1998-07-24 | 2000-02-03 | Bayer Aktiengesellschaft | Substituted benzoylcyclohexandiones |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19914140A1 (de) | 1999-03-27 | 2000-09-28 | Bayer Ag | Substituierte Benzoylpyrazole |
| HRP20010716A2 (en) | 1999-04-01 | 2002-12-31 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| DE19920791A1 (de) | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
| DE19921424A1 (de) | 1999-05-08 | 2000-11-09 | Bayer Ag | Substituierte Benzoylketone |
| DE19929348A1 (de) | 1999-06-26 | 2000-12-28 | Bayer Ag | Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten |
| US6531142B1 (en) | 1999-08-18 | 2003-03-11 | The Procter & Gamble Company | Stable, electrostatically sprayable topical compositions |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| AR027575A1 (es) | 2000-03-06 | 2003-04-02 | Bayer Ag | Benzoilciclohexenonas substituidas |
| US7080644B2 (en) | 2000-06-28 | 2006-07-25 | Microdose Technologies, Inc. | Packaging and delivery of pharmaceuticals and drugs |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US20040071757A1 (en) | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2004083187A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Monocyclic anilide spirohydantoin cgrp receptor antagonists |
| KR20060066141A (ko) | 2003-06-27 | 2006-06-15 | 버글린 코퍼레이션 오브 워싱턴 | 사과 및 연한 코아를 가지거나 피트를 가진 다른 과일들을작은 응력을 가지고 정확하게 코아제거하고슬라이스절단하기 위한 기계 |
| WO2005063754A1 (en) | 2003-12-22 | 2005-07-14 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| BRPI0508522A (pt) | 2004-03-08 | 2007-08-14 | Wyeth Corp | moduladores de canal de ìon |
| WO2005086836A2 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| EP1742932A1 (en) | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
| EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2006117657A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Triazolone derivatives as anti-inflammatory agents |
| DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
| DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| CN103189363B (zh) | 2010-02-27 | 2015-07-29 | 拜耳知识产权有限责任公司 | 双芳基连接的芳基三唑酮及其用途 |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| HUE025729T2 (en) * | 2010-10-01 | 2016-04-28 | Taisho Pharmaceutical Co Ltd | 1,2,4-triazolone derivative |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| HK1206031A1 (en) | 2012-03-22 | 2015-12-31 | 生物区欧洲有限公司 | Antibacterial compounds |
| RS58049B1 (sr) | 2014-11-03 | 2019-02-28 | Bayer Pharma AG | Hidroksialkilom supstituisani derivati feniltriazola i njihova upotreba |
| US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| EP3452457B1 (en) * | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
| AU2017259872B2 (en) * | 2016-05-03 | 2021-06-24 | Bayer Pharma Aktiengesellschaft | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives |
-
2017
- 2017-04-28 US US15/581,064 patent/US9988367B2/en active Active
- 2017-05-02 LT LTEP17720147.2T patent/LT3452463T/lt unknown
- 2017-05-02 UA UAA201811793A patent/UA123791C2/uk unknown
- 2017-05-02 UY UY0001037220A patent/UY37220A/es not_active Application Discontinuation
- 2017-05-02 BR BR112018072542-0A patent/BR112018072542A2/pt not_active IP Right Cessation
- 2017-05-02 PE PE2018002256A patent/PE20190116A1/es unknown
- 2017-05-02 HR HRP20210648TT patent/HRP20210648T1/hr unknown
- 2017-05-02 PL PL17720147T patent/PL3452463T3/pl unknown
- 2017-05-02 AU AU2017259870A patent/AU2017259870B2/en not_active Ceased
- 2017-05-02 WO PCT/EP2017/060356 patent/WO2017191102A1/en not_active Ceased
- 2017-05-02 SI SI201730710T patent/SI3452463T1/sl unknown
- 2017-05-02 AR ARP170101110A patent/AR108262A1/es not_active Application Discontinuation
- 2017-05-02 RS RS20210517A patent/RS61771B1/sr unknown
- 2017-05-02 MX MX2018013335A patent/MX381787B/es unknown
- 2017-05-02 CN CN201780041607.6A patent/CN109415347B/zh not_active Expired - Fee Related
- 2017-05-02 GE GEAP201714945A patent/GEP20207158B/en unknown
- 2017-05-02 ES ES17720147T patent/ES2866109T3/es active Active
- 2017-05-02 EP EP17720147.2A patent/EP3452463B1/en active Active
- 2017-05-02 TN TNP/2018/000368A patent/TN2018000368A1/en unknown
- 2017-05-02 TW TW106114432A patent/TWI772295B/zh not_active IP Right Cessation
- 2017-05-02 GE GEAP202014945A patent/GEAP202014945A/en unknown
- 2017-05-02 KR KR1020187034477A patent/KR20190003655A/ko not_active Abandoned
- 2017-05-02 PT PT177201472T patent/PT3452463T/pt unknown
- 2017-05-02 EA EA201892505A patent/EA035596B1/ru not_active IP Right Cessation
- 2017-05-02 CR CR20180522A patent/CR20180522A/es unknown
- 2017-05-02 JP JP2018557398A patent/JP6932140B2/ja not_active Expired - Fee Related
- 2017-05-02 JO JOP/2017/0105A patent/JOP20170105B1/ar active
- 2017-05-02 MA MA44851A patent/MA44851B1/fr unknown
- 2017-05-02 CU CU2018000134A patent/CU24567B1/es unknown
- 2017-05-02 CN CN202110419086.1A patent/CN113121504A/zh active Pending
- 2017-05-02 US US16/098,308 patent/US20190144423A1/en not_active Abandoned
- 2017-05-02 DK DK17720147.2T patent/DK3452463T3/da active
- 2017-05-02 CA CA3022749A patent/CA3022749A1/en active Pending
- 2017-05-02 SG SG11201809752VA patent/SG11201809752VA/en unknown
- 2017-05-02 HU HUE17720147A patent/HUE053908T2/hu unknown
-
2018
- 2018-05-02 US US15/969,222 patent/US10472348B2/en not_active Expired - Fee Related
- 2018-10-24 IL IL262557A patent/IL262557B/en unknown
- 2018-10-25 PH PH12018502268A patent/PH12018502268A1/en unknown
- 2018-10-26 SV SV2018005771A patent/SV2018005771A/es unknown
- 2018-10-31 EC ECSENADI201881881A patent/ECSP18081881A/es unknown
- 2018-10-31 CL CL2018003105A patent/CL2018003105A1/es unknown
- 2018-11-01 NI NI201800115A patent/NI201800115A/es unknown
- 2018-11-01 DO DO2018000240A patent/DOP2018000240A/es unknown
- 2018-11-02 CO CONC2018/0011933A patent/CO2018011933A2/es unknown
- 2018-11-30 ZA ZA2018/08131A patent/ZA201808131B/en unknown
-
2019
- 2019-09-23 US US16/579,341 patent/US11091463B2/en not_active Expired - Fee Related
-
2021
- 2021-04-27 CY CY20211100366T patent/CY1124084T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514945A5 (enExample) | ||
| HRP20210648T1 (hr) | Amid-supstituirani derivati piridiniltriazola i njihova uporaba | |
| TW544453B (en) | Novel guanidine mimics as factor Xa inhibitors | |
| DE3750687T2 (de) | Angiotensin II-Rezeptorblockierende Imidazole. | |
| JP4680903B2 (ja) | ピリダジニル−ピペラジンおよびそれらのヒスタミンｈ３受容体リガンドとしての使用 | |
| JP4463317B2 (ja) | 置換イミダゾールおよび殺虫剤としてのその使用 | |
| SA517381429B1 (ar) | مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها | |
| AU2014272776C1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| AU2010200135A1 (en) | Novel aryl-and heteroarylpiperazines | |
| JP2010515715A5 (enExample) | ||
| JP2006504658A5 (enExample) | ||
| KR20130004316A (ko) | 비스아릴-결합된 아릴트리아졸론 및 그의 용도 | |
| JP2000514088A (ja) | グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール | |
| JP2010507602A5 (enExample) | ||
| JP2002080453A (ja) | 選択的シクロオキシゲナーゼ−２阻害物質となる置換ピリジン | |
| JP2002520274A (ja) | バルサルタンとカルシウムチャンネルブロッカーの抗高血圧組合わせ | |
| CN106304835A (zh) | sGC刺激剂 | |
| TWI772309B (zh) | 化合物及其於降低尿酸位準之用途(二) | |
| JP2003513961A (ja) | シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物 | |
| AU1732999A (en) | Method of treating heart failure | |
| JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤 | |
| CZ280018B6 (cs) | 4-alkylimidazolové deriváty | |
| JP2014532726A5 (enExample) | ||
| WO2017013010A1 (de) | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung | |
| Carmignani et al. | Novel hypotensive agents from Verbesina c aracasana. 8. Synthesis and pharmacology of (3, 4-Dimethoxycinnamoyl)-N-agmatine and Synthetic Analogues1 |